Novo Nordisk working on new digital solution for treating patients with insulin

Novo Nordisk may soon be introducing a digital solution for patients receiving insulin treatments, as the company is working on a new therapeutic solution.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Digital development at Denmark's largest pharmaceutical company Novo Nordisk is powering ahead.

In recent months, the firm has relaunched its two smart insulin pens in Sweden and launched a phase III trial with its own phone app called Doseguide. Novo Nordisk also tells MedWatch that the company is working towards introducting a digital therapeutic solution to assist patients taking insulin treatments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs